Linaprazan glurate capsules

Gastroesophageal Reflux Disease

Gastroesophageal reflux disease (GERD) is a common digestive disorder characterized by the backflow of stomach contents—such as gastric acid and bile—into the esophagus, leading to uncomfortable symptoms and/or complications. The primary symptoms of this condition include heartburn and regurgitation, but patients may also experience chest pain, upper abdominal discomfort, a burning sensation in the upper abdomen, belching, and other related symptoms. GERD not only affects quality of life but can also lead to serious complications, such as erosive esophagitis, esophageal ulcers, esophageal strictures, and even increase the risk of esophageal adenocarcinoma. Therefore, timely diagnosis and treatment are crucial.

P-CAB vs. PPI Comparison

● P-CABs act swiftly, delivering optimal acid-suppressing effects as early as the first day and providing rapid relief from heartburn and reflux symptoms; in contrast, PPIs take longer to work, typically requiring several days of treatment before symptoms begin to ease.

● P-CAB is not associated with CYP2C19 gene polymorphisms, resulting in minimal inter-individual variability in efficacy; in contrast, PPIs show greater variability in therapeutic response among individuals.

● P-CAB's acid-suppressing effect is unaffected by food, leading to better adherence; in contrast, PPIs must be taken 30 minutes before meals, resulting in relatively lower adherence.

The market for Linara progestin capsules is enormous.

● In the Chinese market worth 30 billion RMB, 200 million Chinese people suffer from acid-related stomach disorders, and more than one-third of these patients rely on traditional proton pump inhibitors (PPIs) without achieving adequate relief.

● Linaprazan glurate capsules are a Class 1.1 new drug, a novel potassium-ion competitive acid blocker (P-CAB).

● A blockbuster product with sales expected to reach 1 to 3 billion RMB annually.

China's 20-Year Pharmaceutical Reform and the 10-Year Journey of Linagliptin Succinate Capsules

Behind the development of every blockbuster drug lies the story of a dedicated core team and investors striving with perseverance. Sinorda was founded in 2010 by Dr. Hu Pingsheng, a pharmacologist with extensive international drug R&D experience. The founding team initiated research on T-cell tumor immunotherapy and novel drug development, which gained support from the National Major New Drug Innovation Program.

Leveraging the team's expertise and innovation experience, Sinorda was invited to participate in multiple international collaborations on innovative drugs. One of these focused on the R&D of Linaprazan Glurate (X842), a new-generation potassium-competitive acid blocker (P-CAB).

In the spring of 2014, after nearly two years of project evaluation, Sinorda launched the significant X842 project in Shanghai’s bustling Bund area. The strategy involved conducting systematic preclinical studies in China while submitting applications for a Class 1.1 new drug globally, aiming to achieve a world-first launch in China. This goal was particularly ambitious, as no P-CAB drug had yet been successfully marketed worldwide at that time.

The innovation of Linaprazan Glurate, a prodrug, lies in its unique molecular structure formed by linking the active metabolite linaprazan with glutaric acid via an ester bond. This clever design allows for rapid peak plasma concentration, extends the drug's half-life, and reduces the potential incidence of adverse reactions.

Between 2014 and 2017, the Linaprazan Glurate project completed all preclinical studies in China, including API synthesis, formulation development, comprehensive pharmacodynamics and pharmacokinetics studies, and OECD GLP-compliant non-clinical safety assessments. The IND application was submitted to the CFDA, with simultaneous applications supporting submissions in Europe and the United States, making it the first P-CAB drug to be submitted concurrently in China, the US, and Europe. In June 2017, China officially joined the ICH, marking the country's entry into the top tier of international new drug research.

In an exciting development in February 2023, the NDA for Linaprazan Glurate was officially accepted by the NMPA. The key Phase II and Phase III clinical trials for reflux esophagitis were led by Beijing Friendship Hospital, Capital Medical University. Linaprazan Glurate became the first globally originated drug incubated locally in China to complete pivotal Phase III trials and submit a NDA in China, laying a solid foundation for its subsequent development in Asia-Pacific, Europe, and the United States. Its successful R&D not only signifies a substantial improvement in China's drug development capabilities but also demonstrates the country's firm strides toward aligning with international standards in innovative drug R&D.

The development of Linaprazan Glurate bears witness to the complete cycle of China's innovative drug landscape, from a period of dormancy to breakthrough. Starting on the eve of the 2015 policy reforms, Sinorda embarked on a forward-looking layout. It navigated through early-stage funding and environmental challenges, and amidst tests posed by the pandemic and changing international landscape, it successfully addressed intellectual property disputes, thereby solidifying the product's global competitiveness. Linaprazan Glurate stands as one of China's earliest developed Class 1 new drugs, a pioneer project in the MAH pilot program, among the first to file for clinical trials in Europe and the US based on preclinical data, and an innovative drug developed and launched first in China.

The ten-year drug R&D journey of Dr. Hu Pingsheng and his team is one of courage, innovation, and persistence. The story of Linaprazan Glurate will inspire future scientists to apply their knowledge and wisdom to bring more health and hope to the world.